drugset / Trial / NCT03547778

Misoprostol in Office Hysteroscopy and Endometrial Biopsy

NCT03547778

Phase 4 Withdrawn University of South Florida
RandomizedParallel-groupDouble-blindPrevention

Summary

We hypothesize that use of vaginal misoprostol will help in reducing the pain scores when used prior to concurrent office hysteroscopy and endometrial biopsy in a particular subgroup of women who are anticipated to require cervical dilatation.

Timeline

Start
2018-09-01
Primary completion
2019-12-31
Completion
2020-03-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Misoprostol Other / unclassified 50 ug Intravenous

Indications

No indication recorded.